Nektar Therapeutics

YTD

ALL

Trade Nektar Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NKTR

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit.

CEO

Howard W. Robin

CEOHoward W. Robin

Employees

Employees61

Headquarters

San Francisco, California

HeadquartersSan Francisco, California

Founded

1990

Founded1990

Employees

Employees61

NKTR Key Statistics

Market cap

1.13B

Market cap1.13B

Price-Earnings ratio

-6.99

Price-Earnings ratio-6.99

Dividend yield

—

Dividend yield—

Average volume

1.05M

Average volume1.05M

High today

$61.99

High today$61.99

Low today

$59.01

Low today$59.01

Open price

$60.95

Open price$60.95

Volume

363.11K

Volume363.11K

52 Week high

$65.79

52 Week high$65.79

52 Week low

$6.48

52 Week low$6.48

NKTR News

Simply Wall St 6d

Nektar Therapeutics Is Up 8.6% After Late-Breaking ACAAI Presentation for Rezpegaldesleukin – Has The Bull Case Changed?

Nektar Therapeutics announced that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin in atopic dermatitis was accepted for a late-breakin...

Analyst ratings

78%

of 9 ratings

Buy

77.8%

Hold

11.1%

Sell

11.1%

People also own

Based on the portfolios of people who own NKTR. This list is generated using Robinhood data, and it’s not a recommendation.